Form 4: Edwards Lifesciences CFO Scott Ullem Reports Stock Transactions

Scott Ullem, CFO of Edwards Lifesciences, reports acquisition and disposal of company stock and derivative securities.

Summary

• Scott Ullem, the Chief Financial Officer of Edwards Lifesciences, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• On May 7, 2025, Ullem disposed of 1,406 shares of common stock at a price of $74.92.
• On May 8, 2025, he acquired 13,400 shares of common stock and 13,400 performance rights.
• Also on May 8, 2025, Ullem was granted options to acquire 75,200 shares of common stock at an exercise price of $74.63, exercisable commencing one month after the grant date in 36 approximately equal monthly installments.
• On May 9, 2025, he exercised options to acquire 11,250 shares at $45.2767 per share and sold the same amount of shares at a weighted average price of $74.4031.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2024.
• Following these transactions, Ullem directly owns 41,098 shares of common stock and indirectly owns 266,318 shares through a trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and don't necessarily reflect a change in the CFO's outlook on the company.

Positives

• The acquisition of 13,400 shares of common stock by the CFO could be seen as a positive signal.

Negatives

• The disposal of 1,406 shares by the CFO could be interpreted negatively, although it's a small amount relative to his total holdings.

Risks

• Executive stock transactions can be driven by various factors, not always indicative of company performance.
• The vesting of performance rights is contingent on achieving certain performance goals, which introduces uncertainty.

Future Outlook

The vesting of restricted stock units and performance rights is subject to future performance and continued employment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the trading activities of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting schedules and performance-based conditions are typical features of such compensation plans.
• Trading activity under 10b5-1 plans is common among corporate executives to avoid accusations of insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, depending on how they interpret the CFO's trading activity.

Key Dates

Keywords

Form 4, insider trading, stock options, stock, Scott Ullem, Edwards Lifesciences, EW, CFO